Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

TCR2 Therapeutics Inc. (TCRR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.8100+0.0500 (+2.84%)
At close: 04:00PM EDT
1.8600 +0.05 (+2.76%)
After hours: 04:16PM EDT
Advertisement
Get access to 40+ years of historical data with Yahoo Finance Plus Essential.
Currency in USD

Valuation Measures4

Yahoo Finance Plus required to access annual data
Annual
Quarterly
Yahoo Finance Plus required to access monthly data
Monthly
Subscribe to Yahoo Finance Plus Essential to download historical data
 
As of Date: 10/5/2022
Current
Market Cap (intraday)
N/A
Enterprise Value
N/A
Trailing P/E
N/A
Forward P/E
N/A
PEG Ratio (5 yr expected)
N/A
Price/Sales (ttm)
N/A
Price/Book (mrq)
N/A
Enterprise Value/Revenue
N/A
Enterprise Value/EBITDA
N/A

Trading Information

Stock Price History

Beta (5Y Monthly) 1.79
52-Week Change 3N/A
S&P500 52-Week Change 3N/A
52 Week High 38.8200
52 Week Low 31.5980
50-Day Moving Average 32.7434
200-Day Moving Average 32.9218

Share Statistics

Avg Vol (3 month) 3262.91k
Avg Vol (10 day) 3335.74k
Shares Outstanding 538.22M
Implied Shares Outstanding 6N/A
Float 826.12M
% Held by Insiders 10.89%
% Held by Institutions 175.29%
Shares Short (Jul 14, 2022) 42.07M
Short Ratio (Jul 14, 2022) 43.45
Short % of Float (Jul 14, 2022) 47.73%
Short % of Shares Outstanding (Jul 14, 2022) 45.36%
Shares Short (prior month Jun 14, 2022) 42.25M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2021
Most Recent Quarter (mrq)Mar 30, 2022

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-17.96%
Return on Equity (ttm)-35.50%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -100.37M
Net Income Avi to Common (ttm)-107.42M
Diluted EPS (ttm)-2.3980
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)232.19M
Total Cash Per Share (mrq)6.02
Total Debt (mrq)53.68M
Total Debt/Equity (mrq)21.03
Current Ratio (mrq)8.01
Book Value Per Share (mrq)7.06

Cash Flow Statement

Operating Cash Flow (ttm)-88.81M
Levered Free Cash Flow (ttm)-61.11M
Advertisement
Advertisement